KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Assets (2016 - 2025)

Ionis Pharmaceuticals has reported Assets over the past 17 years, most recently at $3.5 billion for Q4 2025.

  • Quarterly results put Assets at $3.5 billion for Q4 2025, up 17.32% from a year ago — trailing twelve months through Dec 2025 was $3.5 billion (up 17.32% YoY), and the annual figure for FY2025 was $3.5 billion, up 17.32%.
  • Assets for Q4 2025 was $3.5 billion at Ionis Pharmaceuticals, up from $3.0 billion in the prior quarter.
  • Over the last five years, Assets for IONS hit a ceiling of $3.5 billion in Q4 2025 and a floor of $2.2 billion in Q1 2021.
  • Median Assets over the past 5 years was $2.8 billion (2024), compared with a mean of $2.8 billion.
  • Biggest five-year swings in Assets: fell 27.25% in 2021 and later increased 21.14% in 2023.
  • Ionis Pharmaceuticals' Assets stood at $2.6 billion in 2021, then fell by 2.98% to $2.5 billion in 2022, then increased by 18.0% to $3.0 billion in 2023, then grew by 0.45% to $3.0 billion in 2024, then grew by 17.32% to $3.5 billion in 2025.
  • The last three reported values for Assets were $3.5 billion (Q4 2025), $3.0 billion (Q3 2025), and $3.0 billion (Q2 2025) per Business Quant data.